Ultimovacs
Menu Close ✕
  • About
    • About Ultimovacs
    • Team
    • Board of directors
  • Technology overview
    • Technology overview
    • Immunotherapy
  • Clinical Studies
    • Phase II studies
    • Phase I studies
    • Partnering
    • Expanded access
  • Investors
    • Shares
    • Financial reports
    • Presentations and publications
    • Investor relations contacts
    • Governance
    • Analyst coverage
    • ESG
    • News
  • Contact

Enabling the immune system to fight cancer

Ultimovacs is a biotechcompany developing novel immunotherapies against cancer.

Read more about Ultimovacs

Our mission is to extend and improve the life of patients by directing the immune system against the core of cancer.

We will provide universally accessible solutions.

Company Presentation

Company presentation

Sign up for company news

Press Releases

Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update 6, November, 2024
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation 31, October, 2024
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv 25, October, 2024
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer 11, September, 2024
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 9, September, 2024
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update 21, August, 2024
See all

News

Interview with CEO Carlos de Sousa in Finansavisen TV 14, February, 2024
Video interview with CEO Carlos de Sousa about the company’s recent top-line data readout for NIPU and its implications for UV1 going forward 14, June, 2023
Interview in MedWatch with CMO Jens Bjørheim regarding the NIPU-trial 14, June, 2023
Biostock Article: About the NIPU study and interview with the Director of Medical Affairs at Ultimovacs, Espen Basmo Ellingsen 6, June, 2023
Ultimovacs Presentation at TD Cowen Healthcare Conference 6, March, 2023
Article published in Current Opinion in Oncology: “Therapeutic cancer vaccination against telomerase” 8, February, 2023
See all
E-mail:
mail@ultimovacs.com ir@ultimovacs.com medinfo@ultimovacs.com
Phone number: +47 413 80 080
Ullernchausséen 64
0379 Oslo
Norway View in Google Maps

Technology

  • Technology
  • Clinical studies
  • Immunotherapy

Ultimovacs

  • About Ultimovacs
  • Team
  • Board of directors
  • Contact us

Investors

  • Share information
  • Financial reports
  • Investor relations contacts
  • News
Copyright © Ultimovacs ASA 2024 | Privacy statement